Pipeline
Development & Sales strategies reflecting the characteristics of Radiopharmaceuticals
- | Korea’s first Radiopharmaceutical diagnostic tracer for breast cancer in the market |
- | Medical imaging agent to detect metastatic breast cancer and differentiate the Estrogen receptor status |
Rights & Permissions / Sales | Acquire the rights for Korean domestic market and secure the overseas licensing rights | Drug classification | Diagnosis of breast cancer |
---|---|---|---|
Dates (Approval/Agreement) | Acquired NDA approval on Nov. 2019 | Remarks |
|
Rights & Permissions / Sales | Acquire the rights for Korean domestic market and secure the overseas licensing rights |
---|---|
Drug classification | Diagnosis of breast cancer |
Dates (Approval/Agreement) | Acquired NDA approval on Nov. 2019 |
Remarks |
|
- | Korea’s first Radiopharmaceutical diagnostic tracer for prostate cancer in the market |
- | Open a new era for the diagnosis of metastatic and recurrent prostate |
Rights & Permissions / Sales | For international market | Drug classification | Diagnosis of prostate cancer |
---|---|---|---|
Dates (Approval/Agreement) | June 24, 2019 – Exclusive licensing agreement signed (Approved by US FDA and EMA) |
Remarks |
|
Rights & Permissions / Sales | For international market |
---|---|
Drug classification | Diagnosis of prostate cancer |
Dates (Approval/Agreement) | June 24, 2019 – Exclusive licensing agreement signed (Approved by US FDA and EMA) |
Remarks |
|
- | Developed and launched therapeutic Radiopharmaceutical for the first time in the country |
- | Korea’s first Radiopharmaceutical therapy for Neuroendocrine tumor in the market |
Rights & Permissions / Sales | For approval in Korea | Drug classification | Gastroenteropancreatic Neuroendocrine Tumor Treatment |
---|---|---|---|
Dates (Approval/Agreement) | August 30, 2019 – Exclusive licensing agreement signed | Remarks |
|
Rights & Permissions / Sales | For approval in Korea |
---|---|
Drug classification | Gastroenteropancreatic Neuroendocrine Tumor Treatment |
Dates (Approval/Agreement) | August 30, 2019 – Exclusive licensing agreement signed |
Remarks |
|